Review

LINCOLN PHARMACEUTICALS 

Ticker : 531633
FV: Rs 10
52-Week H/L: Rs 254.90/85.50

We had previously recommended Lincoln Pharmaceuticals in volume 36, issue no. 44 (dated August 24, 2020), when the stock was trading at Rs 237.35. Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing, and distribution of pharmaceutical products. On a consolidated quarterly front, the net sales were reported at Rs 103.79 crore in Q1FY21, up by 7.21 per cent from Rs 96.81 crore in Q1FY20. The operating profit of the company came in at Rs 23.97 crore in Q1FY21, up by 17.82 per cent from Rs 20.34 crore in Q1FY20. In Q1FY21, the net profit was reported at Rs 15.26 crore, up by 20.44 per cent from Rs 12.67 crore in Q1FY20. LPL has become debt-free and has reported a robust set of numbers for the latest quarter. Its strong performance in the domestic & international markets, new product approvals, and better margin products are the key positives. Thus, we recommend investors to HOLD the scrip.